|Day Low/High||0.06 / 0.06|
|52 Wk Low/High||0.04 / 3.46|
July 15, 2013-- Dendreon Corporation (Nasdaq:DNDN) today announced that management will host a conference call on Thursday, August 8, 2013, at 4:30 p.
Stocks with insider trader activity include CPHD, BYI, DNDN, AKAM and FDS
Stocks with insider trader activity include DNDN, BK, TIVO, YUM and GTAT
Investors in Dendreon Corp saw new options become available today, for the July 12th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the DNDN options chain for the new July 12th contracts and identified one put and one call contract of particular interest.
June 28, 2013--Dendreon Corporation (Nasdaq: DNDN) today announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending that ...
Biotech columnist Adam Feuerstein answers readers' questions about healthcare companies.
A lot of investors are betting these 10 biotechs stocks are going to fail. The most-shorted stock may surprise you.
Investors in Dendreon Corp saw new options begin trading today, for the June 7th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the DNDN options chain for the new June 7th contracts and identified one put and one call contract of particular interest.
Investors eyeing a purchase of Dendreon Corp shares, but tentative about paying the going market price of $3.92/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2015 put at the $2 strike, which has a bid at the time of this writing of 53 cents.
An updated list of the biotech and drug firms expecting FDA drug approval decisions in 2013.
Dendreon investor Brad Loncar is tweeting from today's Dendreon annual shareholder meeting.
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
A list of stock-moving biotech catalysts includes FDA drug approvals, clinical trial results and closely-followed medical meetings.
With the negatives coming into focus and the positives still only possibilities, Cramer said investors need to get cautious.
Dendreon Corporation (Nasdaq:DNDN) today announced that it has reached an agreement in principle to settle the securities class action litigation pending against it in the United States District Court for the Western...
March 12, 2013—Dendreon Corporation (NASDAQ:DNDN) today announced that management will present at the 25 th Annual ROTH Conference in Laguna Niguel, California, on March 18, 2013, at 11:00 a.
ISI Group's Mark Schoenebaum offers refreshing mea culpa on Dendreon bullishness.
Crish Lau, Kapitall Contributor Â Companies in the biotechnology space are often trade like speculative investments. Speculation for FDA approvals may [...]
Dendreon Corporation (Nasdaq: DNDN) today reported results for the fourth quarter and full year ended December 31, 2012.
February 13, 2013--Dendreon Corporation (NASDAQ: DNDN) today announced that results from several ongoing or completed studies investigating the utility of PROVENGE ® (sipuleucel-T) in the treatment of advanced...
Once a stock trends to a new high, or takes out a prior overhead resistance point, then it's free to find new buyers and momentum players that can ultimately push the stock significantly higher.
Dendreon Corporation (Nasdaq: DNDN) today announced that management will host a conference call on Monday, February 25, 2012, at 9:00 a.
Dendreon was a winner within the drugs industry, rising 8 cents (1.3%) to $6.33 on light volume.
The five articles written under three different aliases all promoted Galena Biopharma.
Biotech columnist Adam Feuerstein answers readers' questions about health-care companies
Cramer is bullish on Dendreon and Anheuser-Busch Inbev and would love to see Procter& Gamble split itself.
Despite Deerfield Management's interest in this biotech name, we would not recommend it.
Rising short-interest indicates bearishness for the company is building up by investors. Between November 30 2012 and December 14, short-selling [...]
Live, interactive coverage of the biotech and drug companies presenting at the J.P. Morgan Healthcare Conference.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.